All In Biotech

Drug Trial Radar · NCT01660620

Topical Betaxolol for the Prevention of Retinopathy of Prematurity

Last checked: Nov 20, 2026Latest source record: Jan 3, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

Apr 2011

Primary completion

Nov 2011

Study completion Nov 2011

Sponsor

Lead sponsor
Smith-Kettlewell Eye Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ohio State University; University of Minnesota; University of Oklahoma; The University of Texas Health Science Center, Houston
First posted
Aug 8, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 32 weeks, up to 32 weeks
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.

Conditions

  • Development of Side Effects From Betaxolol

Interventions

  • BetaxololDrug

  • topical betaxololDrug

    given topically

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. development of apnea and or bradycardiaTime frame: 3 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.